AIDS and Cancer Specimen Resource (ACSR)

艾滋病和癌症样本资源 (ACSR)

基本信息

批准号：
8739632
负责人：
MICHAEL Shannon MCGRATH
金额：
$ 371.72万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-23 至 2018-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8739632
关键词：
AIDS/HIV problem Acceleration Accounting Acquired Immunodeficiency Syndrome Address Arizona Basic Science Behavioral Biological Biological Markers Biological Preservation Cause of Death Clinical Clinical Data Collection Commit Communities Complement Consultations DNA Library Data Coordinating Center Developing Countries Development Diagnosis Ensure Epidemic Epidemiologic Studies Epidemiology Equipment and supply inventories Foundations Funding Future Goals Grant HIV HIV Infections HIV Seropositivity Image Incidence Individual Industry Institutes Institution Instruction Interdisciplinary Study International Investigation Kaposi Sarcoma Laboratories Leadership Liquid substance Maintenance Malignant Neoplasms Malignant neoplasm of lung Medicine Methods Mission National Cancer Institute Non-Hodgkin&apos s Lymphoma Pathogenesis Patients Population Positioning Attribute Procedures Process Program Evaluation Research Research Infrastructure Research Personnel Resources Role Sampling Scientist Services Silver Slide Specimen Staining method Stains Structure System Technology Time TimeLine Tissue Microarray Tissues Training Translational Research Translations Tumor Tissue United States Universities Validation Washington Work base biobank cancer specimen resource cancer therapy college drug development experience improved innovation insight interest meetings multidisciplinary new technology novel novel diagnostics novel strategies novel therapeutic intervention operation programs prospective public health relevance repository response sample collection success therapeutic target trend tumor virtual web site

项目摘要

DESCRIPTION (provided by applicant): The National Cancer Institute (NCI) established the AIDS and Cancer Specimen Resource (ACSR) in 1994 to support the collection and expert preservation of clinically-annotated biospecimens for multidisciplinary research, bridging laboratory basic science with clinical, behavioral, and epidemiological studies. For the past 19 years, the ACSR has provided the foundation for successful translational research reliant on consistent access to high-quality well-annotated biospecimens. It has accomplished this via development of extensive expertise in methods for specimen collection and maintenance including specimen stability and full functionality overtime. The ACSR remains crucial to HIV-translational research, expanding services to researchers, and instituting practices to complement innovative new experimental directions by global HIV investigators. Since 2008, the current grant cycle, ACSR banked over 50,000 and distributed over 10,000 biospecimens to scientists worldwide. ACSR has also developed unique programs, offering project consultation and researcher training at all levels that assist with specimen choice and inform about biorepository procedures, thus ensuring appropriate handling and use of valuable biospecimens for research. The work accomplished under the current ACSR will be leveraged and transitioned to achieve the Specific Aims for the new ACSR to: 1) develop and maintain the ACSR infrastructure that allows efficient translation of the overall ACSR mission (to support current and future trends in HIV/AIDS malignancy research) to an ongoing functional program 2) provide scientific leadership, expand utilization and relevance of the resource; 3) acquire, maintain and distribute a diverse collection of high-quality and well-annotated biospecimens and; 4) support initiatives, projects, programs and collections, both national and international through ACSR services. To accomplish these aims we will restructure the current ACSR to a single multisite ACSR, under the direction of the Office of the Chairs (OC) and administered by the Central Operations and Data Coordinating Center (CODCC) to be led by senior investigators in a shared leadership role, Drs. Michael McGrath and Sylvia Silver, representing the continuing UCSF and George Washington University (GW) Regional Biospecimen Repositories (RBR). The two original RBRs, UCSF and GW, account for > 80% of the overall ACSR inventory (500,000+ specimens) and for supplying 90% of the specimens disbursed to researchers in the past five years. The proposed ACSR also will add value through transitioning affiliate programs at the University of Arizona, Tucson, and Baylor College of Medicine to new RBRs. The ACSR will continue to evolve and streamline operations to incorporate a state of the art inventory system, and new technologies and methods to improve specimen viability. The ACSR is a dynamic entity that has used innovative and novel approaches to meet changes in the epidemic and research directions, and is well positioned to continue support of current and future trends in HIV research that will have a positive impact on diagnosis and management of HIV-malignancies worldwide.

描述（由申请人提供）：美国国家癌症研究所 (NCI) 于 1994 年建立了艾滋病和癌症样本资源 (ACSR)，以支持临床注释生物样本的收集和专家保存，用于多学科研究，将实验室基础科学与临床、行为学联系起来。和流行病学研究。在过去的 19 年里，ACSR 为成功的转化研究奠定了基础，依赖于持续获取高质量、注释良好的生物样本。它通过在样本采集和维护方法（包括样本稳定性和完整功能加班）方面开发广泛的专业知识来实现这一目标。 ACSR 对于艾滋病毒转化研究、扩大对研究人员的服务以及制定实践以补充全球艾滋病毒研究人员的创新实验方向仍然至关重要。自 2008 年（即当前资助周期）以来，ACSR 已储存了 50,000 多个生物样本，并向世界各地的科学家分发了 10,000 多个生物样本。 ACSR 还制定了独特的计划，提供各级项目咨询和研究人员培训，协助样本选择并告知生物样本库程序，从而确保适当处理和使用有价值的生物样本进行研究。当前 ACSR 下完成的工作将得到利用和过渡，以实现新 ACSR 的具体目标：1) 开发和维护 ACSR 基础设施，以实现整个 ACSR 使命的有效转化（以支持当前和未来的 HIV/艾滋病恶性肿瘤研究) 为一项正在进行的功能性计划 2) 提供科学领导，扩大资源的利用和相关性； 3) 获取、维护和分发各种高质量且注释良好的生物样本； 4) 通过 ACSR 服务支持国内和国际的倡议、项目、计划和收藏。为了实现这些目标，我们将把当前的 ACSR 重组为一个单一的多站点 ACSR，由主席办公室 (OC) 指导并由中央运营和数据协调中心 (CODCC) 管理，该中心由高级调查员领导，共同负责领导作用，博士。 Michael McGrath 和 Sylvia Silver，代表 UCSF 和乔治华盛顿大学 (GW) 区域生物样本库 (RBR)。两个最初的 RBR，UCSF 和 GW，占钢芯绞线总库存（超过 500,000 个样本）的 80% 以上，并且在过去五年中向研究人员提供了 90% 的样本。拟议的 ACSR 还将通过将亚利桑那大学图森分校和贝勒医学院的附属项目过渡到新的 RBR 来增加价值。 ACSR 将继续发展和简化运营，以纳入最先进的库存系统以及提高样本活力的新技术和方法。 ACSR 是一个充满活力的实体，它使用创新和新颖的方法来应对流行病和研究方向的变化，并有能力继续支持艾滋病毒研究当前和未来的趋势，这将对艾滋病毒的诊断和管理产生积极影响- 全世界的恶性肿瘤。